Evidence map›Paper›PMID 36038563›Full record

ArticleScientific reports2022

Genomic epidemiology and emergence of SARS-CoV-2 variants of concern in the United Arab Emirates.

Habiba Alsafar, Mohammed Albreiki, Mira Mousa, Syafiq Kamarul Azman, Hema Vurivi, Fathimathuz Waasia, Dymitr Ruta, Farida Alhosani, Shereena Almazrouei, Rowan Abuyadek and 17 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Habiba Alsafar *Center for Biotechnology, Khalifa University of Science and Technology, PO BOX, 127788, Abu Dhabi, United Arab Emirates.
Mohammed Albreiki *Center for Biotechnology, Khalifa University of Science and Technology, PO BOX, 127788, Abu Dhabi, United Arab Emirates.
Mira MousaCenter for Biotechnology, Khalifa University of Science and Technology, PO BOX, 127788, Abu Dhabi, United Arab Emirates.
Syafiq Kamarul AzmanDepartment of Electrical Engineering and Computer Science, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Hema VuriviCenter for Biotechnology, Khalifa University of Science and Technology, PO BOX, 127788, Abu Dhabi, United Arab Emirates.
Fathimathuz WaasiaCenter for Biotechnology, Khalifa University of Science and Technology, PO BOX, 127788, Abu Dhabi, United Arab Emirates.
Dymitr RutaEmirates ICT Innovation Center (EBTIC), Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Farida AlhosaniAbu Dhabi Public Health Center, Abu Dhabi Department of Health, Abu Dhabi, United Arab Emirates.
Shereena AlmazroueiAbu Dhabi Public Health Center, Abu Dhabi Department of Health, Abu Dhabi, United Arab Emirates.
Rowan AbuyadekAbu Dhabi Public Health Center, Abu Dhabi Department of Health, Abu Dhabi, United Arab Emirates.
Francis SelvarajDepartment Laboratory Medicine Services, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Irene Chaves-CoiraMolecular and Genetics Department, UniLabs, Abu Dhabi, United Arab Emirates.
Val ZvereffDepartment of Molecular Diagnostics, National Reference Laboratory, Abu Dhabi, United Arab Emirates.
Mohamed A Y Abdel-MalekMolecular Biology Laboratory, Mediclinic Alnoor Hospital, Abu Dhabi, United Arab Emirates.
Nawal AlkaabiDepartment of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Maimunah UddinDepartment of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Tayba Al AwadhiMinistry of Health and Prevention, Dubai, United Arab Emirates.
Nada Al MarzouqiMinistry of Health and Prevention, Dubai, United Arab Emirates.
Fatma Al AttarMinistry of Health and Prevention, Dubai, United Arab Emirates.
Safeiya Al ShamsiMinistry of Health and Prevention, Dubai, United Arab Emirates.
Fatima Al ShehhiMinistry of Health and Prevention, Dubai, United Arab Emirates.
Hala AlteneijiMinistry of Health and Prevention, Dubai, United Arab Emirates.
Kalthoom MohamedMinistry of Health and Prevention, Dubai, United Arab Emirates.
Noor Al MuhairiMinistry of Health and Prevention, Dubai, United Arab Emirates.
Hussain AlRandMinistry of Health and Prevention, Dubai, United Arab Emirates.
Asma FikriMinistry of Health and Prevention, Dubai, United Arab Emirates.
Andreas HenschelCenter for Biotechnology, Khalifa University of Science and Technology, PO BOX, 127788, Abu Dhabi, United Arab Emirates. Andreas.Henschel@ku.ac.ae.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the declaration of SARS-CoV-2 outbreak as a pandemic, the United Arab Emirates (UAE) public health authorities have adopted strict measures to reduce transmission as early as March 2020. As a result of these measures, flight suspension, nationwide RT-PCR and surveillance of viral sequences were extensively implemented. This study aims to characterize the epidemiology, transmission pattern, and emergence of variants of concerns (VOCs) and variants of interests (VOIs) of SARS-CoV-2 in the UAE, followed by the investigation of mutations associated with hospitalized cases. A total of 1274 samples were collected and sequenced from all seven emirates between the period of 25 April 2020 to 15 February 2021. Phylogenetic analysis demonstrated multiple introductions of SARS-CoV-2 into the UAE in the early pandemic, followed by a local spread of root clades (A, B, B.1 and B.1.1). As the international flight resumed, the frequencies of VOCs surged indicating the January peak of positive cases. We observed that the hospitalized cases were significantly associated with the presence of B.1.1.7 (p < 0.001), B.1.351 (p < 0.001) and A.23.1 (p = 0.009). Deceased cases are more likely to occur in the presence of B.1.351 (p < 0.001) and A.23.1 (p = 0.022). Logistic and ridge regression showed that 51 mutations are significantly associated with hospitalized cases with the highest proportion originated from S and ORF1a genes (31% and 29% respectively). Our study provides an epidemiological insight of the emergence of VOCs and VOIs following the borders reopening and worldwide travels. It provides reassurance that hospitalization is markedly more associated with the presence of VOCs. This study can contribute to understand the global transmission of SARS-CoV-2 variants.

Indexed as

COVID-19SARS-CoV-2GenomicsHumansPhylogenyUnited Arab Emirates

Identifiers

PMID36038563
PMCPMC9421632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.